Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin

Journal of Medicinal Chemistry

Volumn 41, Issue 13, 1998, Pages 2216-2226

  Fan, Y ^a   Weinstein, J N ^a   Kohn, K W ^a   Shi, L M ^a   Pommier, Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; IRINOTECAN; TOPOTECAN;

ARTICLE; BINDING SITE; COMPLEX FORMATION; COVALENT BOND; DNA CLEAVAGE; DNA REPLICATION; DNA STRAND BREAKAGE; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; BINDING SITES; CAMPTOTHECIN; DNA; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROTEIN CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 0032543518     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9605445     Document Type: Article

References (57)

1. Gupta, M.; Fujimori, A.; Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta 1995, 1262, 1-14.
2. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692.
3. Champoux, J. Mechanistic aspects of type-I topoisomerase; Cold Spring Harbor Laboratory: Cold Spring, 1990.
4. Chen, A. Y.; Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 1994, 94, 194-218.
5. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein- linked DNA breaks via mammalian DNA topoisomerase I. J. Biol Chem. 1985, 260, 14873-14878.
6. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gate keeper and its intruders, camptothecins. Sem. Oncol. 1996, 23, 1-10.
7. Slichenmyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 1993, 85, 271-287.
8. Rothenberg, M. L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 1997, 8, 837-855.
9. Leteurtre, F.; Fesen, M.; Kohlhagen, G.; Kohn, K. W.; Pommier, Y. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 1993, 32, 8955-8962.
10. Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28, 4629-4638.
11. Pommier, Y.; Kohlhagen, G.; Kohn, K. W.; Leteurtre, F.; Wani, M. C.; Wall, M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8861-8865.
12. Jaxel, C.; Capranico, G.; Kerrigan, D.; Kohn, K. W.; Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991, 266, 20418-20423.
13. Wall, M. E.; Wani, M. C. Camptothecin and taxol: discovery to clinic- thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995, 55, 753-760.
14. Pommier, Y.; Jaxel, C.; Heise, C. R.; Kerrigan, D.; Kohn, K. W. Structure- activity relationship by camptothecin derivatives: evidence for the existence of a ternary cleavable complex; Oxford University Press: New York, 1991.
15. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase 1: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989, 49, 1465-1469.
16. Tanizawa, A.; Kohn, K. W.; Pommier, Y. Induction of cleavage in topoisomerase I cDNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucl. Acids Res. 1993, 21, 5157-5166.
17. Porter, S. E.; Champoux, J. J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucl. acids Res. 1989, 17, 8521-8532.
18. Svej́ J. Q.; Christiansen, K. Gromova, I. I.; Anderson, A. H.; Westergaard, O. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J. Mol. Biol. 1991, 222, 669-678.
19. Crow, R. T.; Crothers, D. M. Structural modifications of camptothecin and effects on topoisomerase I inhibition. J. Med. Chem. 1992, 35, 4160-4164.
20. Pommier, Y.; Tanizawa, A.; Kohn, K. W. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv. Pharmacol. 1994, 29B, 73-91.
21. Hertzberg, R. P.; Busby, R. W.; Caranfa, M. J.; Holden, K. G.; Johnson, R. K.; Hecht, S. M.; Kingsbury, W. D. Irreversible trapping of the DNA-topoisomerase I covalent complex. J. Biol. Chem. 1990, 265, 19287-19295.
22. Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S. M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32, 2, 715-720.
23. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; Gallagher, R. P. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase 1 and antitumor activity. J. Med. Chem. 1991, 34, 98-107.
24. Sawada, S.; Nokata, K.; Furuta, T.; Yokokura, T.; Miyasaka, T. Chemical modification of an antitumor alkaloid camptothecin synthesis and antitumor activity of 7-C substituted camptothecins. Chem. Pharm. Bull. 1991, 39, 2574-2580.
25. Emerson, D. L.; Besterman, J. M.; Brown, H. R.; Evans, M. G.; Leitner, P. P.; Luzzio, M. J.; Shaffer, J. E.; Sternbach, D. D.; Uehling, D.; Vuong, A. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res. 1995, 55, 603-609.
26. Hsiang, Y.-H.; Liu, L. F.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase 1-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 1989, 49, 9, 4385-4389.
27. Fujimori, A.; Harker, W. G.; Kohlhagen, G.; Hoki, Y.; Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 1995, 55, 1339-1346.
28. Evans, M. G. Chiral Benzdioxane camptothecins as water-soluble topoisomerase I inhibitors; American Chemical Society Meeting, 1994; p 52.
29. Milstead, M. W. Substituted methylenedioxy camptothecins as water-soluble topoisomerase I inhibitors; American Chemical Society Meeting, 1994; p 51.
30. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 1984, 106, 765-784.
31. Weiner, P. K.; Kollman, P. A. AMBER: assisted model building with energy refinementA general program for modeling molecules and their interactions. J. Comput. Chem. 1981, 287-303.
32. Tripos Associates. Sybyl Molecular Modeling Software, Sybyl theory manual; , 6.1 ed.; Tripos Associates, St. Louis, 1994.
33. Padlan, E. A.; Kabat, E. A. Modeling of antibody complex. Methods Enzymol. 1991, 203, 3-21.
34. Rini, J. M.; Schulze-Gahmen, U.; Wilson, I. A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992, 255, 959-965.
35. McPhail, A. T.; Sim, G. A. The structure of camptothecin: X-ray analysis of camptothecin iodoacetate. J. Chem. Soc. B 1968, 923-928.
36. Sarai, A.; Mazur, J.; Nussinov, R.; Jernigan, R. L. Origin of DNA helical structure and its sequence dependence. Biochemistry 1988, 27, 8498-8502.
37. Sponer, J.; Kypr, J. Relationships among rise, cup, roll and stagger in DNA suggested by empirical potential studies of base stacking. J. Biomol. Struct. Dyn. 1993, 11, 27-41.
38. Dickerson, R. E. Base sequence and helix structure variation in B and A DNA. J. Mol. Biol. 1983, 166, 419-441.
39. Sponer, J.; Hobza, P. Bifurcated hydrogen bonds in DNA crystal structures. An ab initio quantum chemical study. J. Am. Chem. Soc. 1994, 116, 709-714.
40. Hunter, C. A. Sequence-dependent DNA structure. The role of base stacking interactions. J. Mol. Biol. 1993, 230, 1025-1054.
41. Price, S. L.; Stone, A. J. The electrostatic interactions in van der Waals complexes involving aromatic molecules. J. Chem. Pays. 1987, 86, 2859-2863.
42. Covey, J. M.; Jaxel, C.; Kohn, K. W.; Pommier, Y. Protein-linked DNA strand breaks induced in Mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989, 49, 5016-5022.
43. Valenti, M.; Nieves-Neira, W.; Kohlhagen, G.; Kohn, K. W.; Wall, M. E.; Wani, M. C.; Pommier, Y. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol. Pharmacol. 1997, 52, 82-87.
44. Tanizawa, A.; Kohn, K. W.; Kohlhagen, G.; Leteurte, F.; Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives Biochemistry 1995, 34, 7200-7206.
45. Peel, M. R.; Milstead, M. W.; Sternbach, D. D.; Besterman, J. M.; Leitner, P.; Morton, B. Noverl A-ring modified camptothecins as topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 2129-2132.
46. Yaegashi, T.; Sawada, S.; Nagata, H.; Furuta, T.; Yokokura, T.; Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives. A-ring-substituted 7-methyl camptothecin and their E-ring modified water-soluble derivatives. Chem. Pharm. Bull. 1994, 42, 2518-2525.
47. Luzzio, M. J.; Besterman, J. M.; Emerson, D. L.; Evans, M. G.; Lackey, K.; Leitner, P. L.; McIntyre, G.; Morton, B.; Myers, P. L.; Peel, M.; Sisco, J. M.; Sternbach, D. D.; Tong, W.-Q.; Truesdale, A.; Uehling, D. E.; Vuong, A.; Yates, J. Synthesis and antitumor activity of novel water-soluable derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem. 1995, 38, 395-401.
48. Owen, N. L.; Hester, R. E. Vibrational spectra and torsional barriers of anisole and some monohalogen derivatives. Spectrochim. Acta 1969, 25A, 343-354.
49. Grindley, T. B.; Katrizky, A. R.; Topsom, R. D. Infrared intensities as a quantitative measure of intramolecular interactions. Part XXXIV. Quantitative relations between conjugation and strain energies and s_R values: rotational barriers in monosubstituted benzenes. J. Chem. Soc., Perkin Trans. 2 1974, 289-297.
50. Garg, S. K.; Smyth, C. D. Microwave absorption and molecular structure in liquids. LXVIII. Dielectric behavior at 2.2-mm wavelength and intramolecular motion in five substituted benzenes and cyclohexanes. J. Chem. Phys. 1967, 46, 373-377.
51. Vincent, M. A.; Hiller, I. H. A theoretical study of methoxy group rotation in anisole. Chem. Phys. 1990, 140, 35-40.
52. Uehling, D. E.; Nanthakumar, S. S.; Croom, D.; Emerson, D. L.; Leitner, P. P.; Luzzio, M. J.; McIntyre, G.; Morton, B.; Profeta, S.; Sisco, J.; Sternbach, D. D.; Tong, W.-W.; Vuong, A.; Besterman, J. M. Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs. J. Med. Chem. 1995, 55, 1106-1118.
53. Redinbo, M. R.; Stewart, L.; Kuhn, P.; Champoux, J. J.; Hol, W. G. J. Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998, 279, 1504-1513.
54. Stewart, L.; Redinbo, M. R.; Qiu, X.; Hol, W. G. J.; Champoux, J. J. A model for the mechanism of human topoisomerase I. Science 1998, 279, 1534-1541.
55. Nicholas, A. W.; Wani, M. C.; Manikumar, G.; Wall, M. E.; Kohn, K. W.; Pommier, Y. Plant antitumor agents 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin. J. Med. Chem. 1990, 33, 972-978.
56. Fujimori, A.; Hoki, Y.; Popescu, N.; Pommier, Y. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol. Res. 1996, 295-307.
57. Knab, A. M.; Fertala, J.; Bjornsti, M.-A. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J. Biol. Chem. 1993, 268, 22322-22330.